| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 200 | 1,560 | 1,470 | 760 | 3,080 |
| Sales Growth | -87.18% | +6.12% | +93.42% | -75.32% | unch |
| Net Income | -1,110 | -2,880 | -2,470 | -1,100 | -930 |
| Net Income Growth | +61.46% | -16.60% | -124.55% | -18.28% | unch |
Arch Biopartners Inc Ord (ACHFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Arch Biopartners Inc. is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation. Arch Biopartners Inc. is based in TORONTO.
Fiscal Year End Date: 09/30